Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

3 reasons Bernstein strategists are bullish on the EU pharma sector into 2025

admin by admin
January 12, 2025
in Stock
0
3 reasons Bernstein strategists are bullish on the EU pharma sector into 2025
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Investing.com — Bernstein analysts are optimistic about the European pharmaceutical sector as it heads into 2025, despite concerns over policy changes and market headwinds. 

The firm outlined its three key reasons for the positive outlook in a note this week

Solid Growth Prospects: Bernstein forecasts an 8% EPS compound annual growth rate (CAGR) from 2025 to 2030, excluding Novo Nordisk (NYSE:NVO). 

This growth is said to be driven by “broad-based unmet needs, demographics, and pharma’s proven ability to innovate”—factors that allow companies to manage healthcare spending effectively. 

The ability of the sector to continue delivering innovation while addressing pressing medical needs positions it for strong long-term growth, according to the firm

Compelling Valuation: “We believe the sector’s robust fundamentals are mispriced at the current low-20s discount to the global market,” said Bernstein.

As the market begins to recognize the true value of European pharma companies, Bernstein anticipates a potential re-rating that could drive future upside. The analysts also note that the sector’s defensive characteristics make it attractive in uncertain times, especially with the ongoing macroeconomic challenges.

Strong Cash Generation: The EU pharma sector is known for its “well-proven capital allocation track record,” according to the firm. 

Bernstein expects robust cash flow generation that will enable companies to fund productive R&D while maintaining strong dividend growth. 

They add that this financial strength gives companies the flexibility to pursue “disciplined/niche M&A” to further enhance their growth prospects.

Additionally, Bernstein highlights key drivers that could spur a re-rating of the sector, including stability in U.S. drug pricing, better pipeline execution, and the potential reform of U.S. Pharmacy Benefit Managers (PBMs).

 

This post appeared first on investing.com

Previous Post

Goldman Sachs’ 2025 outlook on cybersecurity stocks

Next Post

5 big analyst AI moves: Tesla, AMD, Adobe downgraded; Salesforce top pick for 2025

admin

admin

Next Post
5 big analyst AI moves: Tesla, AMD, Adobe downgraded; Salesforce top pick for 2025

5 big analyst AI moves: Tesla, AMD, Adobe downgraded; Salesforce top pick for 2025

Trending News

Fed expected to cut rate on Thursday. Here’s all you need to know

Fed expected to cut rate on Thursday. Here’s all you need to know

November 7, 2024
ECB’s Kazimir: increasingly confident in disinflation path

ECB’s Kazimir: increasingly confident in disinflation path

October 21, 2024
Expensive Asana stock price could surge by 195% in 2025

Expensive Asana stock price could surge by 195% in 2025

December 22, 2024
Subscribe to Insightful Word


    Recent News

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    June 6, 2025
    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    June 6, 2025
    Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    June 6, 2025
    Starlink reportedly secures key licence in India, moves closer to launching services

    Starlink reportedly secures key licence in India, moves closer to launching services

    June 6, 2025

    Recent News

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    June 6, 2025
    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    June 6, 2025

    Latest News

    • China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll
    • FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more
    • Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.